

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**FORTY-FIRST MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM FEBRUARY 1, 2023 THROUGH FEBRUARY 28, 2023**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	February 1, 2023 through February 28, 2023
Monthly Fees Incurred:	\$125,875.00

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$125,875.00

This is a: X monthly _____interim _____final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$41,462.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$353,078.50	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$447,827.00	\$0.00
Docket No. 2503 Filed on 3/17/2021	12/1/2020 – 12/31/2020	\$308,146.00	\$0.00	\$305,146.00	\$0.00
Docket No. 2504 Filed on 3/17/2021	1/1/2021 – 1/31/2021	\$493,773.50	\$0.00	\$490,773.50	\$0.00
Docket No. 2848 Filed on 5/12/2021	2/1/2021 – 2/28/2021	\$381,199.00	\$9.99	\$377,458.99	\$9.99
Docket No. 2849 Filed on 5/12/2021	3/1/2021 – 3/31/2021	\$513,645.00	\$0.00	\$509,895.00	\$0.00
Docket No. 3017 Filed on 6/11/2021	4/1/2021 – 4/30/2021	\$415,904.00	\$0.00	\$412,154.00	\$0.00
Docket No. 3225 Filed on 7/15/2021	5/1/2021 – 5/31/2021	\$363,711.00	\$40.00	\$360,001.00	\$40.00
Docket No. 3747 Filed on 9/9/2021	6/1/2021 – 6/30/2021	\$303,427.50	\$0.00	\$299,677.50	\$0.00

PRIOR APPLICATIONS (cont.):

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 3798 Filed on 9/21/2021	7/1/2021 – 7/31/2021	\$431,630.50	\$135.81	\$427,880.50	\$135.81
Docket No. 3941 Filed on 10/14/2021	8/1/2021 – 8/31/2021	\$284,159.00	\$20.94	\$280,409.00	\$20.94
Docket No. 4097 Filed on 11/11/2021	9/1/2021 – 9/30/2021	\$244,958.50	\$0.00	\$241,208.50	\$0.00
Docket No. 4225 Filed on 12/15/2021	10/1/2021 – 10/31/2021	\$368,998.50	\$40.00	\$367,498.50	\$40.00
Docket No. 4311 Filed on 1/26/2022	11/1/2021 – 11/30/2021	\$255,094.50	\$1,160.04	\$253,594.50	\$1,160.04
Docket No. 4312 Filed on 1/26/2022	12/1/2021 – 12/31/2021	\$192,786.50	\$0.00	\$191,286.50	\$0.00
Docket No. 4395 Filed on 2/25/2022	1/1/2022 – 1/31/2022	\$314,564.00	\$0.00	\$313,064.00	\$0.00
Docket No. 4654 Filed on 4/12/2022	2/1/2022 – 2/28/2022	\$181,198.50	\$8.00	\$178,888.84	\$8.00
Docket No. 4826 Filed on 5/16/2022	3/1/2022 – 3/31/2022	\$267,504.00	\$44.03	\$265,194.33	\$44.03
Docket No. 4833 Filed on 5/16/2022	4/1/2022 – 4/30/2022	\$175,704.00	\$0.00	\$173,394.33	\$0.00
Docket No. 4950 Filed on 7/12/2022	5/1/2022 – 5/31/2022	\$98,099.50	\$0.00	\$96,849.50	\$0.00
Docket No. 5005 Filed on 8/8/2022	6/1/2022 – 6/30/2022	\$53,624.00	\$0.00	\$52,374.00	\$0.00
Docket No. 5051 Filed on 8/31/2022	7/1/2022 – 7/31/2022	\$53,023.00	\$0.00	\$51,773.00	\$0.00
Docket No. 5132 Filed on 10/12/2022	8/1/2022 – 8/31/2022	\$35,470.00	\$0.00	\$34,220.00	\$0.00
Docket No. 5240 Filed on 11/15/2022	9/1/2022 – 9/30/2022	\$53,219.00	\$8.00	\$52,344.00	\$8.00
Docket No. 5341 Filed on 1/13/2023	10/1/2022 – 10/31/2022	\$30,107.50	\$0.00	\$29,232.50	\$0.00
Docket No. 5342 Filed on 1/13/23	11/1/2022 – 11/30/2022	\$31,105.00	\$0.00	\$30,230.00	\$0.00
Docket No. 5393 Filed on 2/1/23	12/1/2022 – 12/31/2022	\$42,190.00	\$0.00	\$41,315.00	\$0.00
Docket No. 5518 Filed on 3/30/23	1/1/2023 – 1/31/2023	\$98,523.50	\$0.00	\$0.00	\$0.00

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, \$10,000, \$15,000, \$15,000, \$15,000, \$6,000, \$6,929, \$5,000, and \$3,500 were allocated evenly across fees from the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, and tenth interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from February 1, 2023 through and including February 28, 2023 (the “**Fee Period**”) amount to:

Professional Fees	\$125,875.00
Expenses	<u>0.00</u>
TOTAL	<u>\$125,875.00</u>

2. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$100,700.00
Expenses at 100%	<u>0.00</u>
TOTAL	<u>\$100,700.00</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A”**.
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B”**.

5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C”**.
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than April 13, 2023 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
March 30, 2023

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
1166 Avenue of the Americas, 15th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY PROFESSIONAL****FOR THE PERIOD FEBRUARY 1, 2023 TO FEBRUARY 28, 2023**

Professional	Position	Specialty	Billing Rate	Total Hours	Total Fees
Diaz, Matthew	Sr Managing Director	Restructuring	\$ 1,325	23.7	\$ 31,402.50
Shafer, Patterson	Managing Director	Healthcare	675	1.5	1,012.50
Bromberg, Brian	Sr Director	Restructuring	975	56.9	55,477.50
Suric, Emil	Sr Director	Restructuring	975	2.0	1,950.00
Kurtz, Emma	Sr Consultant	Restructuring	750	28.6	21,450.00
Blittner, Jack	Consultant	Restructuring	475	30.7	14,582.50
GRAND TOTAL				143.4	\$ 125,875.00

EXHIBIT B**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD FEBRUARY 1, 2023 TO FEBRUARY 28, 2023**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	5.8	\$ 3,085.00
2	Cash & Liquidity Analysis	2.8	3,325.00
6	Asset Sales	0.9	877.50
7	Analysis of Domestic Business Plan	66.4	57,312.50
9	Analysis of Employee Comp Programs	1.4	1,855.00
13	Analysis of Other Miscellaneous Motions	13.4	10,735.00
16	Analysis, Negotiate and Form of POR & DS	35.9	31,407.50
18	Review of Historical Transactions	1.8	2,315.00
21	General Mtgs with Counsel and/or Ad Hoc Committee	4.2	3,760.00
24	Preparation of Fee Application	3.5	2,970.00
30	Emergence Preparation	7.3	8,232.50
GRAND TOTAL		143.4	\$ 125,875.00

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2023 TO FEBRUARY 28, 2023

Task Category	Date	Professional	Hours	Activity
1	2/7/2023	Kurtz, Emma	0.6	Review recently uploaded dataroom documents re: reporting to share with team.
1	2/8/2023	Blittner, Jack	0.7	Prepare the 2/8 daily update email to the internal team.
1	2/8/2023	Kurtz, Emma	0.4	Review the 2/8 daily process update to provide feedback to the team.
1	2/9/2023	Blittner, Jack	0.2	Prepare the 2/9 daily update email to the internal team.
1	2/10/2023	Blittner, Jack	0.3	Prepare the 2/10 daily update email to the internal team.
1	2/13/2023	Blittner, Jack	0.9	Prepare the 2/13 daily update email to the internal team.
1	2/15/2023	Blittner, Jack	0.6	Prepare the 2/15 daily update email to the internal team.
1	2/17/2023	Blittner, Jack	0.2	Prepare the 2/17 daily update email to the internal team.
1	2/20/2023	Blittner, Jack	0.3	Prepare the 2/20 daily update email to the internal team.
1	2/22/2023	Blittner, Jack	0.7	Prepare the 2/22 daily update email to the internal team.
1	2/23/2023	Blittner, Jack	0.3	Prepare the 2/23 daily update email to the internal team.
1	2/23/2023	Kurtz, Emma	0.2	Finalize the 2/23 daily update email to the internal team.
1	2/28/2023	Blittner, Jack	0.4	Prepare the 2/28 daily update email to the internal team.
1 Total			5.8	
2	2/13/2023	Diaz, Matthew	0.6	Review the Debtors' updated cash position to assess long-term liquidity status.
2	2/14/2023	Bromberg, Brian	1.1	Review the Debtors' latest cash flow projections to evaluate updates.
2	2/20/2023	Diaz, Matthew	1.1	Review of the updated cash reporting analysis received from the Debtors.
2 Total			2.8	
6	2/27/2023	Bromberg, Brian	0.3	Participate in call with the Debtors re: product asset monetization.
6	2/27/2023	Bromberg, Brian	0.6	Review product asset monetization materials to prepare for meeting with the Debtors.
6 Total			0.9	
7	2/1/2023	Bromberg, Brian	0.7	Review business plan presentation from the Debtors.
7	2/1/2023	Bromberg, Brian	1.0	Participate in call with the internal team re: business plan review and internal workplan.
7	2/1/2023	Bromberg, Brian	0.4	Compare prior business plan to the current business plan presentation to evaluate changes.
7	2/1/2023	Diaz, Matthew	0.7	Review updated business plan from the Debtors.
7	2/1/2023	Kurtz, Emma	1.0	Participate in call with the internal team re: case status, business plan review, and upcoming deliverables.
7	2/2/2023	Bromberg, Brian	0.6	Prepare information request list re: business plan for the Debtors.
7	2/2/2023	Bromberg, Brian	0.6	Review slides summarizing business plan updates for governmental creditors presentation.
7	2/2/2023	Bromberg, Brian	0.3	Coordinate with Houlihan re: business plan update for the governmental creditors.
7	2/2/2023	Bromberg, Brian	0.8	Outline key cases issues for presentation for non consenting state group.
7	2/2/2023	Diaz, Matthew	0.8	Finalize the business plan diligence list to be sent to the Debtors.
7	2/2/2023	Shafer, Patterson	0.8	Review documents summarizing the Debtors' transfer of licenses.
7	2/3/2023	Blittner, Jack	1.8	Review updated business plan provided by the Debtors to evaluate latest projections.
7	2/3/2023	Blittner, Jack	1.1	Prepare slides summarizing key business plan updates in preparation for call with the governmental creditors.
7	2/3/2023	Blittner, Jack	0.6	Continue to prepare slides summarizing key business plan updates in preparation for call with the governmental creditors.
7	2/3/2023	Blittner, Jack	0.6	Incorporate updates to slides summarizing key business plan updates based on feedback from the team.
7	2/3/2023	Bromberg, Brian	0.6	Review updated business plan provided by the Debtors to assess draft presentation.
7	2/3/2023	Bromberg, Brian	0.6	Continue to review updated business plan provided by the Debtors to assess draft presentation.
7	2/3/2023	Bromberg, Brian	0.9	Prepare outline of upcoming governmental creditors presentation re: business plan updates.
7	2/3/2023	Diaz, Matthew	0.6	Review draft business plan presentation to provide comments.
7	2/3/2023	Kurtz, Emma	0.9	Compare 2023 business plan to 2022 business plan to evaluate key updates.
7	2/4/2023	Blittner, Jack	1.4	Prepare revisions to slides summarizing business plan updates per internal comments.
7	2/5/2023	Blittner, Jack	1.1	Prepare additional slides to incorporate into governmental creditors update presentation re: business plan updates.
7	2/5/2023	Kurtz, Emma	1.4	Compare Debtors' current business plan to past business plans to provide comments to team on presentation.
7	2/6/2023	Blittner, Jack	2.4	Prepare additional slides to incorporate into business plan update presentation per comments from team.
7	2/6/2023	Blittner, Jack	2.3	Incorporate updates to slides summarizing variance between current and prior business plan.
7	2/6/2023	Bromberg, Brian	1.2	Review slides outlining the variance to past business plan to provide comments to team.
7	2/6/2023	Bromberg, Brian	1.2	Review Debtors' 2022 performance to prepare revisions to slides summarizing 2022 performance.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2023 TO FEBRUARY 28, 2023

Task Category	Date	Professional	Hours	Activity
7	2/6/2023	Bromberg, Brian	1.6	Review slides summarizing business plan updates to provide comments.
7	2/6/2023	Bromberg, Brian	0.7	Review business plan forecast model provided by the Debtors.
7	2/6/2023	Diaz, Matthew	1.2	Review projections and assumptions in Debtors' latest business plan model.
7	2/6/2023	Kurtz, Emma	1.7	Review updated business plan forecast model from the Debtors.
7	2/6/2023	Kurtz, Emma	1.9	Review updated draft business plan presentation to prepare revisions.
7	2/6/2023	Kurtz, Emma	0.9	Continue to review updated draft business plan presentation to prepare revisions.
7	2/7/2023	Blittner, Jack	1.9	Prepare additional revisions to draft business plan presentation re: 2022 performance.
7	2/7/2023	Bromberg, Brian	0.9	Review slides summarizing the Debtors' 2022 performance to provide comments for the team.
7	2/7/2023	Bromberg, Brian	0.4	Finalize draft business plan presentation for Counsel to review.
7	2/7/2023	Bromberg, Brian	0.4	Review redactions provided by the Debtors' to assess changes to the business plan update presentation.
7	2/7/2023	Bromberg, Brian	0.7	Participate in call with the Debtors' professionals re: business plan updates.
7	2/7/2023	Diaz, Matthew	1.9	Review draft business plan presentation to provide feedback to the team.
7	2/7/2023	Kurtz, Emma	1.2	Prepare revisions to slides summarizing the Debtors' updated business for the AHC presentation per comments from team.
7	2/8/2023	Bromberg, Brian	0.6	Finalize business plan update deck in preparation for call with the state AGs.
7	2/9/2023	Diaz, Matthew	0.7	Review outstanding business plan analysis to assess next steps.
7	2/9/2023	Suric, Emil	0.9	Review the Debtors' 2022 business plan to analyze key assumptions.
7	2/10/2023	Bromberg, Brian	0.6	Review the Debtors' business plan to evaluate certain assumptions.
7	2/10/2023	Diaz, Matthew	1.3	Review the Debtors' updated business plan to assess actionable next steps.
7	2/13/2023	Bromberg, Brian	1.2	Review PHI issues received from Debtors' to prepare updated analysis.
7	2/13/2023	Diaz, Matthew	0.7	Review the Debtors' recent HRT funding request to prepare updated HRT analysis.
7	2/14/2023	Blittner, Jack	0.5	Participate in call with the internal team re: business plan review.
7	2/14/2023	Bromberg, Brian	0.5	Participate in call with the internal team re: business plan analysis.
7	2/14/2023	Kurtz, Emma	0.5	Participate in call with the internal team re: business plan updates.
7	2/15/2023	Blittner, Jack	1.9	Review documents received from the Debtors' to assess key business plan assumptions.
7	2/15/2023	Bromberg, Brian	0.7	Review latest business plan received from the Debtors to evaluate changes.
7	2/15/2023	Bromberg, Brian	0.6	Prepare updated diligence request list for the Debtors based on latest business plan received from the Debtors.
7	2/17/2023	Blittner, Jack	1.1	Participate in call with the Debtors re: business plan review and diligence updates.
7	2/17/2023	Bromberg, Brian	1.6	Review the Debtors' updated business plan and diligence request list in preparation for call with the Debtors.
7	2/17/2023	Bromberg, Brian	1.1	Participate in call with the Debtors re: business plan diligence requests.
7	2/17/2023	Bromberg, Brian	0.4	Participate in call with the Debtors' professionals re: business plan updates.
7	2/17/2023	Bromberg, Brian	0.7	Review documents received from the Debtors' related to the updated business plan.
7	2/17/2023	Diaz, Matthew	0.7	Review materials to prepare for call with the Debtors re: latest business plan.
7	2/17/2023	Suric, Emil	1.1	Participate in call with the Debtors re: updated business plan.
7	2/18/2023	Bromberg, Brian	0.4	Draft list of key business plan issues for team.
7	2/21/2023	Bromberg, Brian	0.6	Participate in call with the Debtors' professionals re: business plan updates and review.
7	2/22/2023	Bromberg, Brian	1.2	Review recent documents received from the Debtors re: projected R&D spend, updated budget model, and next steps.
7	2/23/2023	Diaz, Matthew	0.6	Review updated R&D schedules received from the Debtors to assess next steps.
7	2/23/2023	Diaz, Matthew	1.8	Review updated business plan received from the Debtors to identify key updates.
7	2/27/2023	Blittner, Jack	0.5	Participate in call with the internal team re: recent business operations and performance.
7	2/27/2023	Blittner, Jack	0.6	Prepare analysis re: business plan review.
7	2/27/2023	Bromberg, Brian	0.4	Participate in call with the internal team re: business operations and review.
7	2/28/2023	Bromberg, Brian	1.1	Review updated business plan to address questions from the team.
7 Total			66.4	
9	2/24/2023	Diaz, Matthew	1.4	Review the 2023 proposed compensation information.
9 Total			1.4	

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2023 TO FEBRUARY 28, 2023

Task Category	Date	Professional	Hours	Activity
13	2/20/2023	Diaz, Matthew	0.8	Review the 2004 information list.
13	2/23/2023	Bromberg, Brian	0.9	Review HRT funding motion to evaluate terms of request.
13	2/23/2023	Diaz, Matthew	0.7	Review HRT funding motion to evaluate key terms.
13	2/24/2023	Blittner, Jack	1.4	Review HRT funding request to prepare draft slides.
13	2/24/2023	Blittner, Jack	1.4	Continue to prepare slides summarizing HRT funding updates.
13	2/24/2023	Blittner, Jack	1.2	Update the HRT presentation to reflect comments from the team.
13	2/24/2023	Bromberg, Brian	1.8	Review HRT funding motion to address questions from the team.
13	2/24/2023	Bromberg, Brian	0.9	Review HRT funding presentation to provide comments to the team.
13	2/24/2023	Kurtz, Emma	1.4	Review HRT funding motion presentation to provide comments to team.
13	2/27/2023	Blittner, Jack	0.9	Incorporate additional revisions to HRT update presentation per comments from the team.
13	2/27/2023	Bromberg, Brian	0.8	Review updated HRT funding details.
13	2/27/2023	Bromberg, Brian	0.4	Review slides summarizing HRT funding to incorporate updated funding details.
13	2/27/2023	Kurtz, Emma	0.4	Review draft HRT funding motion to prepare revisions to slides.
13	2/28/2023	Bromberg, Brian	0.4	Review HRT funding details to assess updates to HRT update presentation.
13 Total			13.4	
16	2/1/2023	Bromberg, Brian	0.4	Review slides summarizing the distributable value analysis for the upcoming Committee presentation.
16	2/7/2023	Bromberg, Brian	0.7	Review distributable cash flow prior analyses.
16	2/7/2023	Diaz, Matthew	0.7	Participate in call with the Debtors' professionals re: key case issues.
16	2/7/2023	Kurtz, Emma	0.4	Participate in bi-weekly professionals call re: case updates and emergence preparations.
16	2/14/2023	Blittner, Jack	0.7	Review distributable value updates to assess the Debtors' latest assumptions.
16	2/14/2023	Bromberg, Brian	0.8	Review distributable value cash flow analysis from Houlihan to assess updated projections.
16	2/14/2023	Bromberg, Brian	0.9	Review distributable value cash flow model key issues.
16	2/14/2023	Bromberg, Brian	1.4	Review slides summarizing distributable value analysis to provide comments to the team.
16	2/14/2023	Kurtz, Emma	0.6	Update distributable value model to reflect latest assumptions received from the Debtors.
16	2/15/2023	Blittner, Jack	1.4	Incorporate updates to the distributable value model based on information received from the Debtors.
16	2/15/2023	Bromberg, Brian	0.3	Review insurance issues and potential impact on distributable values.
16	2/15/2023	Kurtz, Emma	1.1	Prepare analysis of timing adjustments for distributable value model and identify necessary updates.
16	2/15/2023	Kurtz, Emma	1.3	Prepare updates to distributable value model to reflect latest business plan assumptions.
16	2/15/2023	Kurtz, Emma	1.2	Review draft distributable value model updates to prepare revisions.
16	2/16/2023	Bromberg, Brian	1.7	Review distributable value analysis to provide feedback to the team.
16	2/16/2023	Bromberg, Brian	1.2	Review plan B cash flow.
16	2/16/2023	Kurtz, Emma	1.4	Incorporate updates to the distributable value model based on comments from team.
16	2/20/2023	Bromberg, Brian	0.6	Review updated distributable value analysis to provide feedback to the team.
16	2/21/2023	Bromberg, Brian	0.7	Prepare for call with the Debtors' professionals re: business updates.
16	2/21/2023	Bromberg, Brian	0.3	Review updated assumptions in the distributable value analysis to provide guidance to team.
16	2/22/2023	Bromberg, Brian	1.1	Incorporate updates to the distributable value model based on updated information received from the Debtors.
16	2/23/2023	Bromberg, Brian	1.9	Review updated distributable value cash flow model and variance to prior version.
16	2/23/2023	Bromberg, Brian	1.1	Review prior Houlihan cash flow analysis to assess updates to assumptions.
16	2/23/2023	Bromberg, Brian	0.9	Review revised distributable value cash flow analysis to provide further comments.
16	2/23/2023	Bromberg, Brian	2.3	Prepare cash flow analysis re: Knoa distributions.
16	2/24/2023	Bromberg, Brian	0.6	Review updated distributable value recovery analysis.
16	2/24/2023	Bromberg, Brian	0.8	Review updated distributable value model to provide further comments.
16	2/24/2023	Kurtz, Emma	1.7	Prepare additional revisions to distributable value model to incorporate latest Knoa cash flows.
16	2/27/2023	Bromberg, Brian	0.4	Review cash emergence analysis to provide comments to team.
16	2/27/2023	Bromberg, Brian	1.9	Review distributable value model to provide additional comments.
16	2/27/2023	Kurtz, Emma	1.2	Prepare revisions to distributable value model per comments from team.
16	2/27/2023	Kurtz, Emma	2.2	Prepare draft presentation re: distributable value to NOAT.
16	2/28/2023	Bromberg, Brian	0.7	Review distributable value model to provide feedback to team.
16	2/28/2023	Kurtz, Emma	1.3	Prepare revisions to distributable value model and accompanying slides per comments from team.
16 Total			35.9	

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2023 TO FEBRUARY 28, 2023

Task Category	Date	Professional	Hours	Activity
18	2/13/2023	Diaz, Matthew	0.8	Review updated Sackler asset positions to evaluate changes.
18	2/20/2023	Bromberg, Brian	0.2	Review outstanding information requests re: the Sackler A-Side and B-Side balance sheets.
18	2/20/2023	Diaz, Matthew	0.8	Review updated Sackler financial status to assess next steps.
18 Total			1.8	
21	2/8/2023	Blittner, Jack	1.3	Participate in call with the state AGs re: case updates.
21	2/8/2023	Bromberg, Brian	0.7	Review materials to prepare for call with the state AGs.
21	2/8/2023	Bromberg, Brian	1.3	Participate in call with the state AGs re: case issues and business plan updates.
21	2/14/2023	Diaz, Matthew	0.9	Participate in call with the working group re: strategic alternatives.
21 Total			4.2	
24	2/3/2023	Diaz, Matthew	0.6	Review draft of 10th interim fee application to provide feedback to the team.
24	2/3/2023	Kurtz, Emma	2.3	Prepare draft of 10th interim fee application to comply with bankruptcy code.
24	2/7/2023	Kurtz, Emma	0.4	Prepare revisions to draft 10th interim fee application.
24	2/14/2023	Kurtz, Emma	0.2	Finalize 10th interim fee application to be filed.
24 Total			3.5	
30	2/1/2023	Bromberg, Brian	0.7	Participate in call with Counsel re: emergence workstreams.
30	2/1/2023	Diaz, Matthew	0.7	Participate in call with Counsel re: emergence considerations.
30	2/1/2023	Diaz, Matthew	0.9	Review emergence considerations in preparation for call with Counsel.
30	2/1/2023	Shafer, Patterson	0.7	Participate in call with Counsel re: emergence considerations and transfers of licenses.
30	2/2/2023	Bromberg, Brian	0.8	Participate in call with the Debtors re: key emergence issues.
30	2/2/2023	Diaz, Matthew	0.8	Participate in call with the Debtors re: emergence considerations and next steps.
30	2/2/2023	Diaz, Matthew	0.4	Review emergence considerations and updates in preparation for call with the Debtors.
30	2/2/2023	Kurtz, Emma	0.8	Participate in call with the Debtors re: emergence considerations.
30	2/14/2023	Diaz, Matthew	0.6	Review Debtors' emergence considerations presentation to evaluate key issues.
30	2/27/2023	Diaz, Matthew	0.9	Review emergence issues and workstreams.
30 Total			7.3	
Grand Total			143.4	